{"nctId":"NCT00789854","briefTitle":"Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","startDateStruct":{"date":"2008-11"},"conditions":["Major Depressive Disorder","Treatment Resistant Depression"],"count":688,"armGroups":[{"label":"Add-on Quetiapine XR+SSRI/Venlafaxine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Quetiapine XR","Drug: SSRI/Venlafaxine"]},{"label":"Add-on Lithium+SSRI/Venlafaxine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lithium carbonate","Drug: SSRI/Venlafaxine"]},{"label":"Monotherapy Quetiapine XR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Quetiapine XR"]}],"interventions":[{"name":"Quetiapine XR","otherNames":["Seroquel XR"]},{"name":"Lithium carbonate","otherNames":["Quilonum Retard"]},{"name":"SSRI/Venlafaxine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the Diagnostic and Statistical Manual of Mental disorders, 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode\n* Current episode of depression present, at least 42 days prior to enrolment but not more than 18 months\n* MADRS-Score ≥ 25 at enrolment and randomisation\n\nExclusion Criteria:\n\n* Patients with a DSM-IV Axis I disorder other than MDD within 6 months of randomisation\n* Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status\n* Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk, or have made a suicide attempt within the past 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)","description":"Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"0.843"},{"groupId":"OG001","value":"-17.2","spread":"0.826"},{"groupId":"OG002","value":"-14.9","spread":"0.97"}]}]}]},{"type":"PRIMARY","title":"Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)","description":"Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.9","spread":"0.806"},{"groupId":"OG001","value":"-15.1","spread":"0.797"},{"groupId":"OG002","value":"-13.3","spread":"0.801"}]}]}]},{"type":"SECONDARY","title":"Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients","description":"Number of patients in remission, with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure","description":"Number of patients in remission with one previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure","description":"Number of patients in remission with two previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8","description":"Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤8. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12","description":"Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤12. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients","description":"Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure","description":"Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure","description":"Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients","description":"Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where lower value shows a larger improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.54","spread":"1.24"},{"groupId":"OG001","value":"-1.85","spread":"1.34"},{"groupId":"OG002","value":"-1.58","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure","description":"Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.42","spread":"1.17"},{"groupId":"OG001","value":"-1.91","spread":"1.31"},{"groupId":"OG002","value":"-1.62","spread":"1.27"}]}]}]},{"type":"SECONDARY","title":"Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure","description":"Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"1.30"},{"groupId":"OG001","value":"-1.79","spread":"1.36"},{"groupId":"OG002","value":"-1.54","spread":"1.38"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression Scale (CGI-S), All Patients","description":"Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale form 1-7, where a lower value shows a larger improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":"0.101"},{"groupId":"OG001","value":"-1.65","spread":"0.099"},{"groupId":"OG002","value":"-1.49","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure","description":"Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.45","spread":"0.133"},{"groupId":"OG001","value":"-1.82","spread":"0.13"},{"groupId":"OG002","value":"-1.59","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure","description":"Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":"0.133"},{"groupId":"OG001","value":"-1.55","spread":"0.131"},{"groupId":"OG002","value":"-1.45","spread":"0.135"}]}]}]},{"type":"SECONDARY","title":"Change in Beck Depression Inventory (BDI)","description":"Self-rating assessment of depressive symptoms using Beck Depression Inventory (BDI). Scale from 0-63, where a lower value shows a larger improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"0.926"},{"groupId":"OG001","value":"-13.5","spread":"0.921"},{"groupId":"OG002","value":"-12.2","spread":"0.922"}]}]}]},{"type":"SECONDARY","title":"Change in Pain, Measured by Visual Analog Scale (VAS)","description":"Self-rating assessment of pain using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.47","spread":"1.695"},{"groupId":"OG001","value":"-8.03","spread":"1.681"},{"groupId":"OG002","value":"-8.3","spread":"1.682"}]}]}]},{"type":"SECONDARY","title":"Change in Anxiety Measured by Visual Analog Scale (VAS)","description":"Self-rating assessment of anxiety using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.2","spread":"1.972"},{"groupId":"OG001","value":"-23.4","spread":"1.947"},{"groupId":"OG002","value":"-20.6","spread":"1.952"}]}]}]},{"type":"SECONDARY","title":"Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory","description":"Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"0.347"},{"groupId":"OG001","value":"0.014","spread":"0.344"},{"groupId":"OG002","value":"-0.87","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Change in Anxiety Measured by STAI, Trait Anxiety Inventory","description":"Self-rating assessment of anxiety measured by State-Trait Anxiety Inventory (STAI), trait anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"0.331"},{"groupId":"OG001","value":"-1.36","spread":"0.328"},{"groupId":"OG002","value":"-1.39","spread":"0.331"}]}]}]},{"type":"SECONDARY","title":"Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4","description":"Sleeping quality measured by Montgomery-Asberg Depression Rating Scale (MADRS) item 4 (reduced sleep) (Scale 0-6, where a lower value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"0.108"},{"groupId":"OG001","value":"-2.4","spread":"0.107"},{"groupId":"OG002","value":"-1.63","spread":"0.108"}]}]}]},{"type":"SECONDARY","title":"Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)","description":"Self-rated sleeping quality measured by PSQI (Scale 0-21, subscales 0-3, 18 questions, where a lower value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.77","spread":"0.36"},{"groupId":"OG001","value":"-4.96","spread":"0.358"},{"groupId":"OG002","value":"-3.51","spread":"0.364"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component","description":"Self rating assessment of quality in life using SF-36, mental component (Scale 0-100, where a higher value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.59","spread":"0.929"},{"groupId":"OG001","value":"10.77","spread":"0.925"},{"groupId":"OG002","value":"9.66","spread":"0.932"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component","description":"Self rating assessment of quality in life using SF-36, physical component (Scale 0-100, where a higher value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.224","spread":"0.811"},{"groupId":"OG001","value":"5.065","spread":"0.813"},{"groupId":"OG002","value":"4.566","spread":"0.817"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility","description":"Self rating assessment of quality in life using EQ-5D utility (Scale 0-100, where a higher value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.184","spread":"0.023"},{"groupId":"OG001","value":"0.224","spread":"0.023"},{"groupId":"OG002","value":"0.208","spread":"0.023"}]}]}]},{"type":"SECONDARY","title":"Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)","description":"Self rating assessment of working productivity using WPAI:GH (Scale 0 to number of hours worked during a week multiplied with the salary in Euro, a lower value shows a larger improvement)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-233","spread":"0.023"},{"groupId":"OG001","value":"-185","spread":"0.023"},{"groupId":"OG002","value":"-299","spread":"0.023"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients","description":"The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm (225, 229 or 221).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"131","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure","description":"The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures","description":"The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":228},"commonTop":["Somnolence","Fatigue","Dry mouth","Headache","Sedation"]}}}